Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy

被引:6
作者
Lee, Sang-Ahm [1 ]
Heo, Kyoung [2 ]
Kim, Won-Joo [2 ]
Song, Hong-Ki [3 ]
Kim, Sung-Eun [4 ]
Kim, Sang-Ho [5 ]
No, Soon-Kee [6 ]
Lee, Byung-In [2 ]
机构
[1] Univ Ulsan, Dept Neurol, Seoul, South Korea
[2] Yonsei Univ, Dept Neurol, Seoul 120752, South Korea
[3] Hallym Inst Epilepsy Res, Dept Neurol, Seoul, South Korea
[4] Inje Univ, Dept Neurol, Pusan, South Korea
[5] Dong A Univ, Dept Neurol, Pusan, South Korea
[6] Bong Seng Mem Hosp, Dept Neurol, Pusan, South Korea
来源
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | 2010年 / 19卷 / 06期
关键词
Carbamazepine; Oxcarbazepine; Switching; Partial epilepsy; DOUBLE-BLIND; MONOTHERAPY; TRIAL; RECOMMENDATIONS; MULTICENTER; SEIZURES;
D O I
10.1016/j.seizure.2010.05.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We assessed the clinical variables predicting the feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy. Thirty patients aged 15 years or older with refractory partial epilepsy, who had been treated with slow-release carbamazepine as monotherapy or in combination therapy, were switched overnight from slow-release carbamazepine (mean dose at switching, 900 mg/day) to oxcarbazepine. Of these 30 patients, 29(96.7%) had been treated with a slow-release formulation of carbamazepine. The proportion of patients with polytherapy was 85.3%. Overall, 9 of 30 (30%) switched patients experienced clinically significant adverse events until 2 weeks after switching, including 2 with seizure aggravation. The only clinical variable related to the failure of overnight switching was the number of seizures at baseline. (C) 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:356 / 358
页数:3
相关论文
共 11 条
[1]   Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch [J].
Albani, F ;
Grassi, B ;
Ferrara, R ;
Turrini, R ;
Baruzzi, A .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2004, 13 (04) :254-263
[2]  
Albani F, 2007, FUNCT NEUROL, V22, P111
[3]  
Barcs G, 2000, EPILEPSIA, V41, P1597
[4]   Oxcarbazepine monotherapy for partial-onset seizures - A multicenter, double-blind, clinical trial [J].
Beydoun, A ;
Sachdeo, RC ;
Rosenfeld, WE ;
Krauss, GL ;
Sessler, N ;
Mesenbrink, P ;
Kramer, L ;
D'Souza, J .
NEUROLOGY, 2000, 54 (12) :2245-2251
[5]  
FRIIS ML, 1993, ACTA NEUROL SCAND, V87, P224
[6]   Clinical pharmacokinetics of oxcarbazepine [J].
May, TW ;
Korn-Merker, E ;
Rambeck, B .
CLINICAL PHARMACOKINETICS, 2003, 42 (12) :1023-1042
[7]   Oxcarbazepine - Double-blind, randomized, placebo-control, monotherapy trial for partial seizures [J].
Schachter, SC ;
Vazquez, B ;
Fisher, RS ;
Laxer, KD ;
Montouris, GD ;
Combs-Cantrell, DT ;
Faught, E ;
Willmore, LJ ;
Morris, GL ;
Ojemann, L ;
Bennett, D ;
Mesenbrink, P ;
D'Souza, J ;
Kramer, L .
NEUROLOGY, 1999, 52 (04) :732-737
[8]   Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy:: a consensus view [J].
Schmidt, D ;
Arroyo, S ;
Baulac, M ;
Dam, M ;
Dulac, O ;
Friis, ML ;
Kälviäinen, R ;
Krämer, G ;
van Parys, J ;
Pedersen, B ;
Sachdeo, R .
ACTA NEUROLOGICA SCANDINAVICA, 2001, 104 (03) :167-170
[9]   Oxcarbazepine for Treatment of Partial Epilepsy: A Review and Recommendations for Clinical Use [J].
Schmidt, Dieter ;
Sachdeo, Rajesh .
EPILEPSY & BEHAVIOR, 2000, 1 (06) :396-405
[10]   Clinical recommendations for oxcarbazepine [J].
Smith, PEM .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2001, 10 (02) :87-91